Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #98155 on Biotech Values
DewDiligence
07/01/10 6:41 AM
#98167 RE: Profit_Ace #98155
During an interview, [DNDN’s COO Hans] Bishop also elaborated on the comparative figures for widely used cancer treatments that Dendreon considered in its pricing process. The standard of care in late-stage prostate cancer is Sanofi's chemotherapy treatment Taxotere. Direct per-patient costs for Taxotere amount to only $18,000 per patient, but when indirect costs are included, such as supportive care, the total is actually about $60,000, according to Dendreon.